Ovarian cancer treatment and survival trends among women older than 65 Years of Age in the United States, 1995-2008

Obstetrics and Gynecology

Volumn 127, Issue 1, 2016, Pages 81-89

  Lin, Jenny J ^a   Egorova, Natalia ^a   Franco, Rebeca ^a   Prasad Hayes, Monica ^a   Bickell, Nina A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

AGED; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; COMPARATIVE STUDY; CONFERENCE PAPER; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MEDICARE; MULTIMODALITY CANCER THERAPY; OVARY CANCER; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL TIME; UNITED STATES; VERY ELDERLY; ADJUVANT CHEMOTHERAPY; CANCER REGISTRY; CANCER STAGING; EPIDEMIOLOGY; MORTALITY; NEOADJUVANT THERAPY; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OVARIAN NEOPLASMS; PATHOLOGY; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CYTOREDUCTION SURGICAL PROCEDURES; FEMALE; HUMANS; NEOADJUVANT THERAPY; NEOPLASM STAGING; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; SEER PROGRAM; SURVIVAL RATE; UNITED STATES;

EID: 84952716965     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0000000000001196     Document Type: Conference Paper

References (32)

1. United States Cancer Statistics: 1999-2010 Incidence and mortality web-based report. Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute; 2013. Available at: www.cdc.gov/uscs. Retrieved August 29, 2014.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
3. Britain NIfHaCEG, Britain NCCfCG. Ovarian cancer: The recognition and initial management of ovarian cancer [electronic resource]/developed for NICE by the National Collaborating Centre for Cancer. Cardiff (UK): National Collaborating Centre for Cancer; 2011.
4. Welch HG, Schwartz LM, Woloshin S. Are increasing 5-year survival rates evidence of success against cancer? JAMA 2000; 283:2975-8.
5. Pujade-Lauraine E. How to approach patients in relapse. Ann Oncol 2012;23(suppl 10):x128-31.
6. Fairfield KM, Lucas FL, Earle CC, Small L, Trimble EL, Warren JL. Regional variation in cancer-directed surgery and mortality among women with epithelial ovarian cancer in the Medicare population. Cancer 2010;116:4840-8.
7. Goff BA, Matthews BJ, Wynn M, Muntz HG, Lishner DM, Baldwin LM. Ovarian cancer: patterns of surgical care across the United States. Gynecol Oncol 2006;103:383-90.
8. van Altena AM, Karim-Kos HE, de Vries E, Kruitwagen RF, Massuger LF, Kiemeney LA. Trends in therapy and survival of advanced stage epithelial ovarian cancer patients in the Netherlands. Gynecol Oncol 2012;125:649-54.
9. Thrall MM, Gray HJ, Symons RG, Weiss NS, Flum DR, Goff BA. Trends in treatment of advanced epithelial ovarian cancer in the Medicare population. Gynecol Oncol 2011;122: 100-6.
10. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 2002;40(suppl):IV-3-18.
11. Klabunde CN, Harlan LC, Warren JL. Data sources for measuring comorbidity: A comparison of hospital records and medicare claims for cancer patients. Med Care 2006;44:921-8.
12. Fritz AG, ed. International classification of diseases for oncology: ICD-O. 3rd ed. Geneva (Switzerland): World Health Organization; 2000.
13. Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, et al. Evaluation of new platinumbased treatment regimens in advanced-stage ovarian cancer: A phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol 2009;27:1419-25.
14. van der Burg ME, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1995;332:629-34.
15. van Walraven C, Austin PC, Jennings A, Quan H, Forster AJ. A modification of the elixhauser comorbidity measures into a point system for hospital death using administrative data. Med Care 2009;47:626-33.
16. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care 1998;36: 8-27.
17. Gerestein CG, Nieuwenhuyzen-de Boer GM, Eijkemans MJ, Kooi GS, Burger CW. Prediction of 30-day morbidity after primary cytoreductive surgery for advanced stage ovarian cancer. Eur J Cancer 2010;46:102-9.
18. Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, Karlan BY. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol 1999;72:278-87.
19. Guidozzi F, Ball JH. Extensive primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol 1994; 53:326-30.
20. Chi DS, Zivanovic O, Levinson KL, Kolev V, Huh J, Dottino J, et al. The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas. Gynecol Oncol 2010;119: 38-42.
21. Eisenkop SM, Spirtos NM, Montag TW, Nalick RH, Wang HJ. The impact of subspecialty training on the management of advanced ovarian cancer. Gynecol Oncol 1992;47:203-9.
22. Aletti GD, Santillan A, Eisenhauer EL, Hu J, Aletti G, Podratz KC, et al. A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of shortterm outcomes for ovarian cancer using a risk-Adjusted model. Gynecol Oncol 2007;107:99-106.
23. Patankar S, Burke WM, Hou JY, Tergas AI, Huang Y, Ananth CV, et al. Risk stratification and outcomes of women undergoing surgery for ovarian cancer. Gynecol Oncol 2015; 138:62-9.
24. Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010; 363:943-53.
25. Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24 (suppl 6):vi24-32.
26. Kuo TM, Mobley LR, Bazzoli GJ. Changes in the health care safety net 1992-2003: disparities in access for uninsured persons in Florida. Int J Health Serv 2013;43:551-66.
27. Bazzoli GJ, Lee W, Hsieh HM, Mobley LR. The effects of safety net hospital closures and conversions on patient travel distance to hospital services. Health Serv Res 2012;47:129-50.
28. Bristow RE, Chang J, Ziogas A, Randall LM, Anton-Culver H. High-volume ovarian cancer care: survival impact and disparities in access for advanced-stage disease. Gynecol Oncol 2014; 132:403-10.
29. Fader AN, Rose PG. Role of surgery in ovarian carcinoma. J Clin Oncol 2007;25:2873-83.
30. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-Analysis. J Clin Oncol 2002;20:1248-59.
31. Barber EL, Rutstein S, Miller WC, Gehrig PA. A preoperative personalized risk assessment calculator for elderly ovarian cancer patients undergoing primary cytoreductive surgery. Gynecol Oncol 2015 [Epub ahead of print].
32. Stashwick C, Post MD, Arruda JS, Spillman MA, Behbakht K, Davidson SA, et al. Surgical risk score predicts suboptimal debulking or a major perioperative complication in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. Int J Gynecol Cancer 2011;21:1422-7.